title: A critical overview on ticagrelor in acute coronary syndromes.
abstract: Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.
authors.affiliation: Department of Cardiology and Internal Medicine, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Skłodowskiej-Curie Street No 9, 85-094 Bydgoszcz, Poland. eliano.navarese@alice.it
authors.forename: E P
authors.initials: EP
authors.lastname: Navarese
authors.forename: A
authors.initials: A
authors.lastname: Buffon
authors.forename: M
authors.initials: M
authors.lastname: Kozinski
authors.forename: K
authors.initials: K
authors.lastname: Obonska
authors.forename: M
authors.initials: M
authors.lastname: Rychter
authors.forename: V
authors.initials: V
authors.lastname: Kunadian
authors.forename: D
authors.initials: D
authors.lastname: Austin
authors.forename: S
authors.initials: S
authors.lastname: De Servi
authors.forename: A
authors.initials: A
authors.lastname: Sukiennik
authors.forename: J
authors.initials: J
authors.lastname: Kubica
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D058919:Purinergic P2 Receptor Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D000077486:Ticagrelor; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D000077144:Clopidogrel; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine; D001241:Aspirin